Young Hearts Run Free

Garikipati, Venkata Naga Srikanth; Kishore, Raj

doi:10.1161/circresaha.117.310574

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[16] In addition, recent studies showed that CSC secretome exhibited therapeutic benefits similar to CSCs for the treatment of cardiovascular disease. [17,[21][22][23] The platelet membrane is conjugated with PGE 2 which is expected to both enhance targeting to cardiovascular cells and facilitate the endogenous repair through PGE 2 /EP receptor signaling after I/R injury (Figure 1A). As a novel biomimetic therapeutic nanoparticle, PINC offers the following advantages compared to natural stem cells:…”

Section: Introductionmentioning

confidence: 99%

Platelet‐Inspired Nanocells for Targeted Heart Repair After Ischemia/Reperfusion Injury

Huang

et al. 2018

Adv Funct Materials

106

112

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of mortality in the world. While reperfusion therapy is vital for patient survival post-heart attack, it also causes further tissue injury, known as myocardial ischemia/reperfusion (I/R) injury in clinical practice. Exploring ways to attenuate I/R injury is of clinical interest for improving post-ischemic recovery. A platelet-inspired nano-cell (PINC) that incorporates both prostaglandin E2 (PGE 2 )-modified platelet membrane and cardiac stromal cellsecreted factors to target the heart after I/R injury is introduced. By taking advantage of the natural infarct-homing ability of platelet membrane and the overexpression of PGE 2 receptors (EPs) in the pathological cardiac microenvironment after I/R injury, the PINCs can achieve targeted delivery of therapeutic payload to the injured heart. Furthermore, a synergistic treatment efficacy can be This article is protected by copyright. All rights reserved. 3 achieved by PINC, which combines the paracrine mechanism of stem cell therapy with the PGE 2 /EP receptor signaling that is involved in the repair and regeneration of multiple tissues. In a mouse model of myocardial I/R injury, intravenous injection of PINCs results in augmented cardiac function and mitigated heart remodeling, which is accompanied by the increase in cycling cardiomyocytes, activation of endogenous stem/progenitor cells, and promotion of angiogenesis. This approach represents a promising therapeutic delivery platform for treating I/R injury.

show abstract